WallStSmart

MiniMed Group, Inc. Common Stock (MMED)vsVeeva Systems Inc Class A (VEEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Veeva Systems Inc Class A generates 11% more annual revenue ($3.20B vs $2.89B). VEEV leads profitability with a 28.4% profit margin vs -7.3%. VEEV earns a higher WallStSmart Score of 69/100 (B-).

MMED

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 5.0Value: 5.0Quality: 5.0

VEEV

Strong Buy

69

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 9.3Quality: 7.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MMED.

VEEVUndervalued (+29.2%)

Margin of Safety

+29.2%

Fair Value

$249.97

Current Price

$184.15

$65.82 discount

UndervaluedFair: $249.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMED1 strengths · Avg: 10.0/10
Operating MarginProfitability
136.0%10/10

Strong operational efficiency at 136.0%

VEEV6 strengths · Avg: 8.5/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

PEG RatioValuation
0.838/10

Growing faster than its price suggests

Operating MarginProfitability
29.4%8/10

Strong operational efficiency at 29.4%

Revenue GrowthGrowth
16.0%8/10

16.0% revenue growth

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Areas to Watch

MMED4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-53.00M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-7.3%1/10

Currently unprofitable

VEEV1 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MMED

The strongest argument for MMED centers on Operating Margin. Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : VEEV

The strongest argument for VEEV centers on Debt/Equity, Profit Margin, PEG Ratio. Profitability is solid with margins at 28.4% and operating margin at 29.4%. Revenue growth of 16.0% demonstrates continued momentum.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : VEEV

The primary concerns for VEEV are P/E Ratio.

Key Dynamics to Monitor

MMED profiles as a turnaround stock while VEEV is a growth play — different risk/reward profiles.

VEEV is growing revenue faster at 16.0% — sustainability is the question.

VEEV generates stronger free cash flow (107M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VEEV scores higher overall (69/100 vs 37/100), backed by strong 28.4% margins and 16.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Veeva Systems Inc Class A

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

Visit Website →

Want to dig deeper into these stocks?